Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

Stopped early · Phase 1/Phase 2

Conditions studied: Deep Venous Thrombosis

In brief

This study will evaluate the safety profile of GMI-1271 and its effect on thrombus resolution in patients with distal calf vein Deep Venous Thrombosis (DVT).

Key facts

Study ID

NCT02744833

Run by

GlycoMimetics Incorporated

People needed

2

Starts

2016-07-01

Expected to finish

2016-11-01

Last updated by the study team

2019-06-14

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-75 years
• Male or female
• Diagnosed with acute isolated calf vein Deep Venous Thrombosis (DVT)
• Willing and able to participate in all required evaluations and procedures in this study protocol

You may not qualify if…

• History or presence of clinically significant medical condition or disease in the opinion of the principal investigator
• Uncontrolled acute life-threatening bacterial, viral or fungal infection
• Unable to be treated with systemic anticoagulants
• Current use of immunosuppressants, antiplatelets (other than aspirin), anticoagulants, and/or anti-epileptics
• Diagnosis of acute leukemia or multiple myeloma undergoing active treatment or maintenance treatment within the past 5 years
• Current or recent cancer treatment
• Major surgery within 21 days or planned surgery during the study period
• Female subjects who are pregnant or breastfeeding
• Known history of HIV, Hepatitis B or Hepatitis C
• Alcoholism or drug use
• Clinically significant cardiovascular disease

Where it is running

• University of Michigan — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.